Abstracts

144 – T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV

Background Vaccination to enhance HIV-specific T-cell immunity may be important for HIV cure strategies. GS-1966+GS-1144 is a novel heterologous vaccine regimen comprising GS-1966 (chimpanzee adenovirus vector) and GS-1144 (self-amplifying mRNA-lipid nanoparticle), both encoding a novel conserved HIV-1 immunogen that spans Gag, Pol, and Nef. This regimen was safe and well tolerated in a phase 1b study…

142 – Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays

Background Generating robust virus-specific CD8+ T cell responses is the major objective of most HIV therapeutic vaccines. However, standard T cell assays fail to distinguish whether vaccine-expanded T cell populations are boosted pre-existing responses and/or newly-recruited clonotypes. Here, we utilized two single cell T cell receptor (TCR) sequencing approaches to characterize CD8+ T cell clonotypes…

140 – Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV

Background Monkeypox virus (MPXV) is a zoonotic virus endemic to Africa that has recently spread globally, becoming the first human orthopoxvirus (OPXV) since smallpox eradication. The MPXV global outbreak strain (Clade IIb, lineage B) derives from Clade IIb lineage A strains that circulate and remain endemic to Africa with limited human-to-human transmission. Clinically, lineage A-infected…

149 – Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs

Background Many HIV cure trials use time-to-rebound during an analytic treatment interruption (ATI) as a primary outcome measurement. In a previously described ATI study with no intervention, the fraction of replication-competent outgrowth viruses neutralized by contemporaneous autologous neutralizing antibodies (aNAbs) prior to ART interruption correlated with time to rebound. Therefore, aNAbs may also contribute to…

148 – Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge

Background Non-human primate (NHP) and human clinical studies highlight the utility of broadly neutralizing antibodies (bNAbs) for immunoprophylaxis against HIV-1. Passively delivered bNAbs protect against viral strains susceptible to antibody-mediated neutralization.  To protect against HIV-1 strains resistant to individual antibodies, endeavors to improve bNAb breadth are required.  A key strategy to enhance the neutralization breadth…